The closing price of Gritstone bio Inc. (NASDAQ: GRTS) was $2.59 for the day, up 1.57% from the previous closing price of $2.55. In other words, the price has increased by $+0.0400 from its previous closing price. On the day, 509474 shares were traded. GRTS stock price reached its highest trading level at $2.6100 during the session, while it also had its lowest trading level at $2.4200.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
Our analysis of GRTS’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 5.30 and its Current Ratio is at 5.30. In the meantime, Its Debt-to-Equity ratio is 0.11 whereas as Long-Term Debt/Eq ratio is at 0.11.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Piper Sandler on October 31, 2022, initiated with a Overweight rating and assigned the stock a target price of $6.
On August 22, 2022, Goldman Downgraded its rating to Sell which previously was Neutral but kept the price unchanged to $2.
For the stock, the TTM Price-to-Sale (P/S) ratio is 12.52 while its Price-to-Book (P/B) ratio in mrq is 1.31.
Stock Price History:
Over the past 52 weeks, GRTS has reached a high of $5.85, while it has fallen to a 52-week low of $1.71. The 50-Day Moving Average of the stock is 2.9316, while the 200-Day Moving Average is calculated to be 2.9126.
GRTS traded an average of 875.27K shares per day over the past three months and 790.66k shares per day over the past ten days. A total of 86.89M shares are outstanding, with a floating share count of 81.20M. Insiders hold about 2.59% of the company’s shares, while institutions hold 40.50% stake in the company. Shares short for GRTS as of Jan 30, 2023 were 1.83M with a Short Ratio of 2.55M, compared to 1.87M on Dec 29, 2022. Therefore, it implies a Short% of Shares Outstanding of 2.20% and a Short% of Float of 2.26%.
The firm’s stock currently is rated by 5 analysts. On average, analysts expect EPS of -$0.34 for the current quarter, with a high estimate of -$0.3 and a low estimate of -$0.41, while EPS last year was -$0.37. The consensus estimate for the next quarter is -$0.36, with high estimates of -$0.28 and low estimates of -$0.45.
Analysts are recommending an EPS of between -$1.23 and -$1.57 for the fiscal current year, implying an average EPS of -$1.38. EPS for the following year is -$1.4, with 5 analysts recommending between -$1.15 and -$1.69.
It is expected that $90B in revenue will be generated in the current quarter, according to 5 analysts. It ranges from a high estimate of $3.5M to a low estimate of $2.5M. As of the current estimate, Gritstone bio Inc.’s year-ago sales were $3.06M, an estimated decrease of -5.40% from the year-ago figure. For the next quarter, 5 analysts are estimating revenue of $3.74M, a decrease of -48.00% less than the figure of -$5.40% in the same quarter last year. There is a high estimate of $6M for the next quarter, whereas the lowest estimate is $2.5M.
A total of 5 analysts have provided revenue estimates for GRTS’s current fiscal year. The highest revenue estimate was $19.2M, while the lowest revenue estimate was $18.18M, resulting in an average revenue estimate of $18.59M. In the same quarter a year ago, actual revenue was $48.21M, down -61.40% from the average estimate. Based on 5 analysts’ estimates, the company’s revenue will be $15.09M in the next fiscal year. The high estimate is $24M and the low estimate is $10M. The average revenue growth estimate for next year is down -18.80% from the average revenue estimate for this year.